Search

Displaying results 3481 - 3490 of 10000 in total
  1. Drug

    Etrolizumab

    go.drugbank.com/drugs/DB12189
    Investigational

    [A244564, A244584] Etrolizumab is a humanized IgG1κ monoclonal antibody directed against the β7 subunit of gastrointestinal α4β7 and αEβ7 integrins that, due to its target specificity, appears as or more … [A244574] In the case of [natalizumab], which targets the α4 integrin subunit, this has also resulted in undesirable blockade of lymphocyte CNS trafficking and reported cases of progressive multifocal

  2. Drug

    Human immunoglobulin G

    go.drugbank.com/drugs/DB00028
    ApprovedInvestigational

    IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. … IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population.

    Products: Gammagard S/d, Gamastan S/d
  3. Drug

    DG041

    go.drugbank.com/drugs/DB05027
    Experimental

    DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. … It block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk.

  4. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]

  5. Drug

    Levocabastine

    go.drugbank.com/drugs/DB01106
    Approved

    Levocabastine was discovered at Janssen Pharmaceutica in 1979.

  6. Drug

    Trastuzumab botidotin

    go.drugbank.com/drugs/DB17413
    Experimental

    A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable

  7. Drug

    Narsoplimab

    go.drugbank.com/drugs/DB16418
    ApprovedInvestigational

    [A241030] Evidence increasingly points to a role for the complement system in TMA. … [A241045, A241050] Approved by the FDA on December 24, 2025, narsoplimab-wuug is indicated for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults

    Synonyms: IMMUNOGLOBULIN G4-LAMBDA, ANTI-(HOMO SAPIENS MANNAN-BINDING LECTIN SERINE PROTEASE 2 (MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASE 2, EC=3.4.21.104) HUMAN MONOCLONAL ANTIBODY .GAMMA.4 HEAVY CHAIN
  8. Drug

    Chlormezanone

    go.drugbank.com/drugs/DB01178
    ApprovedWithdrawn

    A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.

    Synonyms: 2-(p-chlorphenyl)-3-methyl-1,3-perhydrothiazin-4-on-1,1-dioxide
  9. Drug

    Samarium (153Sm) lexidronam

    go.drugbank.com/drugs/DB05273
    Approved

    The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain.

  10. Drug

    Levcromakalim

    go.drugbank.com/drugs/DB21154
    Investigational

    Levcromakalim has a monoisotopic molecular weight of 286.13 Da. … Levcromakalim is under investigation in clinical trial NCT04853797 (Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM)).